2024年美国临床肿瘤学会（ASCO）年会即将于5月31日至6月4日在美国芝加哥盛大召开。作为全球肿瘤研究领域的顶尖盛会之一，本次会议将涵盖各肿瘤领域的研究成果、治疗方法和临床实践经验，为肿瘤治疗领域带来新的突破和希望。其中，LBA研究（Late-Breaking Abstracts）作为ASCO大会的“重头戏”，因汇聚各肿瘤领域最前沿、最具创新性的研究成果，更是备受瞩目。本文提前对血液肿瘤领域的LBA研究进行梳理，以供大家参考。
01
LBA6500-ASC4FIRST, a pivotal phase 3 study of asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS TKIs) in newly diagnosed patients (pts) with chronic myeloid leukemia (CML): Primary results
中文标题：asciminib（ASC）vs. 研究者选择的酪氨酸激酶抑制剂（IS TKIs）在新诊断慢性髓系白血病（CML）患者中的关键性3期研究ASC4FIRST：初步结果
报告人及单位：Timothy P. Hughes, MD, FRCPA, FRACP | South Australian Health and Medical Research Institute and University of Adelaide
报告类型：口头报告
报告时间：当地时间5月31日14:45
报告地点：S100bc
02
LBA6508-Multi-site randomized trial of a collaborative palliative and oncology care model for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) receiving non-intensive therapy
中文标题：对接受非强化治疗的急性髓系白血病（AML）和骨髓增生异常综合征（MDS）患者进行姑息和肿瘤协作护理模式的多中心随机试验
报告人及单位：Areej El-Jawahri, MD | Massachusetts General Hospital
报告类型：口头报告
报告时间：当地时间5月31日17:09
报告地点：S100bc
03
LBA7000-Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study
中文标题：BrECADD vs. BEACOPP在晚期经典霍奇金淋巴瘤中的耐受性和疗效：随机研究GHSG HD21
报告人及单位：Borchmann Peter, MD | University Hospital of Cologne, and Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), and German Hodgkin Study Group (GHSG)
报告类型：口头报告
报告时间：当地时间6月1日15:00
报告地点：S100bc
04
LBA7003-Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study
中文标题：Tucidinostat联合R-CHOP治疗既往未经治疗的MYC和BCL2双表达弥漫性大B细胞淋巴瘤：来自III期DEB研究的期中分析
报告人及单位：Weili Zhao, PhD | Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
报告类型：口头报告
报告时间：当地时间6月1日16:00
报告地点：S100bc
05
LBA7005-Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study
中文标题：Brentuximab vedotin联合来那度胺和利妥昔单抗治疗复发/难治性弥漫性大B细胞淋巴瘤患者的疗效：来自3期ECHELON-3研究的结果
报告人及单位：Jeong A Kim, MD | St. Vincent’s Hospital, The Catholic University of Korea
报告类型：口头报告
报告时间：当地时间6月1日16:24
报告地点：S100bc
06
LBA7074-HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory diffuse large B-cell lymphoma: A single agent phase IIa trial
中文标题：HDAC I/IIb选择性抑制剂甲磺酸普依司他治疗复发和难治性弥漫性大B细胞淋巴瘤：单药IIa期试验
报告人及单位：Lijuan Chen, PhD | Department of Hematology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University
报告类型：壁报展示
报告时间：当地时间6月3日9:00
报告地点：Hall A